Shilpa Medicare Limited (SML) began its operations in 1987 as an API manufacturer in Raichur, Karnataka, India, and commenced commercial production by November 1989. Over time, the company has grown into a globally recognized name, offering cost-effective APIs and formulations to various regulated markets worldwide.
SML provides a comprehensive suite of services designed to support researchers and clients involved in Contract Development and Manufacturing (CDMO) projects.
We deliver premium-quality intermediates and final APIs, offering affordable, innovative solutions to meet the needs of advanced scientific research.
Our formulation development team specializes in creating and supplying a wide range of dosage forms, aligning with international quality benchmarks to address diverse therapeutic needs.
Shilpa has emerged as one of the few companies that possess integrated capabilities across development, manufacturing, and commercialization in the complex landscape of generic pharmaceuticals.
With a strong emphasis on Research and Development, Shilpa Medicare has transformed into a knowledge-centric organization, focused on delivering innovative, accessible, and effective treatments.
The company operates five manufacturing units, with four of them based in India, underscoring its commitment to quality and operational excellence.
